Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PMVP with free AI briefings, catalyst countdowns, and dilution alerts.

PMVP · PMV Pharmaceuticals, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$108.5M Cash on Hand
19.9mo Cash Runway
Follow PMVP by email Get an email when PMVP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PMVP, unsubscribe in one click. Privacy

📣 What PMVP Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Rezatapopt (PC14586) Advanced Solid Tumor Phase 1/2 · NCT04585750 Recruiting
[14C]-PC14586 Healthy Male Volunteers Phase 1 · NCT05523687 Completed
midazolam hydrochloride syrup TP53 Y220C Mutation Phase 1 · NCT07372625 Recruiting
Rabeprazole Healthy Volunteers Phase 1 · NCT06054464 Completed
Rosuvastatin TP53 Y220C Mutation Phase 1 · NCT07372625 Recruiting

Also used in these trials (approved or third-party drugs, not PMVP's own candidates): Pembrolizumab, Azacitidine, Famotidine, Itraconazole, Metformin Hydrochloride, Repaglinide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PMVP holds $108.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $16.4M/quarter from operations, an estimated runway of 19.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 62 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PMVP files for a raise →

👥 Who Owns PMVP

Insiders 7.6% Other 5%+ holders 27.1% Institutions (76 holders) 52.6% Public and other holders 12.7%
HolderTypeShares% of sharesAs of
Srinivas Akkaraju 5%+ holder (13G) 7,577,467 10.03% 2026-09-02
TANG CAPITAL MANAGEMENT, LLC 5%+ holder (13G) 7,572,727 10.03% 2026-09-30
BML Investment Partners, L.P. 5%+ holder (13G) 5,292,000 7.01% 2025-12-31
ORBIMED ADVISORS LLC
10% owner
Insider 4,975,291 6.59% 2025-10-23
David Henry Mack
President and CEO, Director · +1.87M options
Insider 508,087 0.67% 2025-10-27
Robert Ticktin
General Counsel & COO · +319,270 options
Insider 98,695 0.13% 2025-07-01
Deepika Jalota
Chief Development Officer · +819,084 options
Insider 89,959 0.12% 2025-07-01
Michael Carulli
Chief Financial Officer · +655,000 options
Insider 73,848 0.10% 2026-03-05

Share count 75,534,742 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full PMVP picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PMVP and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.